Correction to: Blood Cancer Journal https://doi.org/10.1038/s41408-023-00826-6, published online 13 April 2023
Following the publication of this article an error was noted in Fig. 1. In the original publication, in panel A of Fig. 1, an incorrect Western blot for PBX3 was inadvertently used during the preparation of the figure.
The correct Western blot for PBX3 in panel A of Fig. 1 is presented below. The correction of this figure does not affect the reported results or the conclusions of the article.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Fiskus, W., Mill, C.P., Birdwell, C. et al. Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. 15, 99 (2025). https://doi.org/10.1038/s41408-025-01306-9
Published:
DOI: https://doi.org/10.1038/s41408-025-01306-9
